Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

  • Oh, Dongryul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jong Hoon (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2020.06.08
  • Accepted : 2020.07.08
  • Published : 2020.08.05
Download PDF
⟨ Previous Next ⟩

Abstract

Surgical resection is the mainstay of treatment for locally advanced esophageal cancer. Neoadjuvant therapy is recommended to improve survival, based on the results of several randomized trials and meta-analyses. However, controversy remains regarding how to combine surgery, radiotherapy, and chemotherapy. Moreover, in East Asia, the predominant histological type is esophageal squamous cell carcinoma, which has a different epidemiology and tumor biology from esophageal or gastroesophageal junctional adenocarcinoma. As such, the management of esophageal cancer in East Asia seems to be different from that in Western countries. Thus, this article reviews the current evidence on neoadjuvant therapy and considers the optimal combinations and ongoing strategies of multimodal therapy for esophageal squamous cell carcinoma.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
  2. Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013;62:1406-14. https://doi.org/10.1136/gutjnl-2012-302412
  3. Statistics Korea. Cause of death [Internet]. Daejeon: Statistics Korea; 2018 [cited 2020 Jun 3]. Available from: http://kosis.kr.
  4. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013;381:400-12. https://doi.org/10.1016/S0140-6736(12)60643-6
  5. Xi M, Yang Y, Zhang L, et al. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: impact of histology on recurrence patterns and outcomes. Ann Surg 2019;269:663-70. https://doi.org/10.1097/sla.0000000000002670
  6. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):v50-7. https://doi.org/10.1093/annonc/mdw329
  7. Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019;17:855-83. https://doi.org/10.6004/jnccn.2019.0033
  8. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus 2019;16:1-24. https://doi.org/10.1007/s10388-018-0641-9
  9. Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. https://doi.org/10.1056/NEJMoa1112088
  10. Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014;32:2416-22. https://doi.org/10.1200/JCO.2013.53.6532
  11. Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018;36:2796-803. https://doi.org/10.1200/JCO.2018.79.1483
  12. Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8. https://doi.org/10.1016/S1470-2045(15)00040-6
  13. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84. https://doi.org/10.1056/NEJM199812313392704
  14. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33. https://doi.org/10.1016/S0140-6736(02)08651-8
  15. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Longterm results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062-7. https://doi.org/10.1200/JCO.2009.22.2083
  16. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-25. https://doi.org/10.1200/JCO.2006.10.4760
  17. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907), Ann Surg Oncol 2012;19:68-74. https://doi.org/10.1245/s10434-011-2049-9
  18. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study: JCOG9204. J Clin Oncol 2003;21:4592-6. https://doi.org/10.1200/jco.2003.12.095
  19. Klevebro F, Alexandersson von Dobeln G, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016;27:660-7. https://doi.org/10.1093/annonc/mdw010
  20. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. https://doi.org/10.1016/S1470-2045(11)70142-5
  21. Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 2013;43:752-5. https://doi.org/10.1093/jjco/hyt061
  22. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-7. https://doi.org/10.1200/JCO.2005.00.034
  23. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-8. https://doi.org/10.1200/JCO.2005.04.7118
  24. Hategan M, Cook N, Prewett S, Hindmarsh A, Qian W, Gilligan D. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. Dis Esophagus 2015;28:612-8. https://doi.org/10.1111/dote.12242
  25. Matsuda S, Tsubosa Y, Niihara M, et al. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Ann Surg Oncol 2015;22:1866-73. https://doi.org/10.1245/s10434-014-4337-7
  26. Liao Z, Zhang Z, Jin J, et al. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 2004;60:1484-93. https://doi.org/10.1016/j.ijrobp.2004.05.056
  27. Nomura M, Oze I, Kodaira T, et al. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis, Int J Clin Oncol 2016;21:890-8. https://doi.org/10.1007/s10147-016-0963-3
  28. Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg 2016;101:2148-54. https://doi.org/10.1016/j.athoracsur.2015.12.056
  29. Yen YC, Chang JH, Lin WC, et al. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques. Cancer 2017;123:2043-53. https://doi.org/10.1002/cncr.30565
  30. Swisher SG, Winter KA, Komaki RU, et al. A phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 2012;82:1967-72. https://doi.org/10.1016/j.ijrobp.2011.01.043
  31. Ito Y, Takeuchi H, Ogawa G, et al. A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909). J Clin Oncol 2018;36(15_suppl):4051. https://doi.org/10.1200/JCO.2018.36.15_suppl.4051
  32. Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol 2015;33:3866-73. https://doi.org/10.1200/JCO.2014.59.9092
  33. Noordman BJ, Spaander MC, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 2018;19:965-74. https://doi.org/10.1016/S1470-2045(18)30201-8
  34. Noordman BJ, Wijnhoven BP, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 2018;18:142. https://doi.org/10.1186/s12885-018-4034-1
  35. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2013;86:885-91. https://doi.org/10.1016/j.ijrobp.2013.04.006
  36. Chun SG, Skinner HD, Minsky BD. Radiation therapy for locally advanced esophageal cancer. Surg Oncol Clin N Am 2017;26:257-76. https://doi.org/10.1016/j.soc.2016.10.006
  37. Lin SH, Zhang N, Godby J, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer 2016;122:917-28. https://doi.org/10.1002/cncr.29857
  38. Chuong MD, Hallemeier CL, Jabbour SK, et al. Improving outcomes for esophageal cancer using proton beam therapy. Int J Radiat Oncol Biol Phys 2016;95:488-97. https://doi.org/10.1016/j.ijrobp.2015.11.043
  39. Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys 2017;99:667-76. https://doi.org/10.1016/j.ijrobp.2017.06.2450
  40. Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol 2020;38:1569-79. https://doi.org/10.1200/jco.2020.38.15_suppl.1569

Cited by

  1. Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma vol.21, pp.1, 2020, https://doi.org/10.3892/ol.2020.12329